TABLE 4.
Estimated number of new cancer cases by age in Afghanistan female population, 2020.
| Cancer | Total | 0–14 | 15–39 | 40–44 | 45–49 | 50–54 | 55–59 | 60–64 | 65–69 | 70+ | Crude Rate | ASR (World) | Cum. risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast | 3173 (26.44%) | 871 | 386 | 393 | 379 | 340 | 287 | 221 | 296 | 16.7 | 28.9 | 4.3 | |
| Cervix uteri | 1200 (10.00%) | 1 | 394 | 169 | 161 | 142 | 114 | 86 | 59 | 74 | 6.3 | 10.4 | 1.4 |
| Stomach | 807 (6.72%) | 2 | 67 | 43 | 58 | 77 | 98 | 115 | 117 | 230 | 4.3 | 8.9 | 2.31 |
| Corpus uteri | 519 (4.32%) | 102 | 68 | 74 | 73 | 66 | 55 | 40 | 41 | 2.7 | 4.9 | 0.69 | |
| Ovary | 495 (4.12%) | 11 | 180 | 58 | 58 | 54 | 45 | 35 | 25 | 29 | 2.6 | 4.1 | 0.53 |
| Colorectum | 490 (4.08%) | 70 | 33 | 35 | 43 | 54 | 65 | 71 | 119 | 2.6 | 5.1 | ‐ | |
| Leukemia | 472 (3.93%) | 175 | 160 | 25 | 23 | 22 | 20 | 16 | 13 | 18 | 2.5 | 2.9 | 0.33 |
| Esophagus | 451 (3.76%) | 1 | 41 | 22 | 32 | 41 | 52 | 63 | 67 | 132 | 2.4 | 5.0 | 1.29 |
| Brain, central nervous system | 427 (3.56%) | 78 | 170 | 34 | 32 | 29 | 25 | 21 | 16 | 22 | 2.3 | 3.0 | 0.38 |
| Lung | 400 (3.33%) | 3 | 67 | 27 | 34 | 39 | 45 | 50 | 49 | 86 | 2.1 | 4.1 | 0.9 |
| Liver | 403 (3.36%) | 15 | 43 | 13 | 21 | 30 | 41 | 51 | 55 | 134 | 2.1 | 4.4 | 1.35 |
| Lip, oral cavity | 295 (2.46%) | 4 | 53 | 29 | 33 | 35 | 35 | 33 | 28 | 45 | 1.6 | 2.9 | 0.53 |
| Non‐Hodgkin lymphoma | 236 (1.97%) | 31 | 90 | 20 | 19 | 18 | 16 | 13 | 11 | 18 | 1.2 | 1.8 | 0.27 |
| Kidney | 222 (1.85%) | 48 | 47 | 17 | 19 | 20 | 19 | 17 | 14 | 21 | 1.2 | 1.8 | 0.28 |
| Thyroid | 195 (1.62%) | 3 | 64 | 19 | 22 | 23 | 21 | 17 | 12 | 14 | 1.0 | 1.7 | 0.22 |
| Pancreas | 143 (1.19%) | 17 | 7 | 9 | 13 | 17 | 21 | 20 | 39 | 0.75 | 1.6 | 0.4 | |
| Hodgkin lymphoma | 99 (0.82%) | 14 | 63 | 4 | 2 | 5 | 4 | 3 | 3 | 1 | 0.52 | 0.57 | 0.05 |
| Gallbladder | 95 (0.79%) | 5 | 6 | 9 | 11 | 12 | 15 | 13 | 24 | 0.5 | 1.1 | 0.26 | |
| Bladder | 78 (0.65%) | 4 | 14 | 7 | 8 | 8 | 7 | 8 | 8 | 14 | 0.41 | 0.76 | 0.16 |
| Multiple myeloma | 59 (0.49%) | 15 | 7 | 3 | 6 | 6 | 5 | 5 | 12 | 0.31 | 0.57 | 0.13 | |
| Hypopharynx | 54 (0.45%) | 10 | 5 | 7 | 8 | 7 | 6 | 5 | 6 | 0.28 | 0.52 | 0.08 | |
| Oropharynx | 47 (0.39%) | 2 | 5 | 5 | 8 | 5 | 5 | 4 | 6 | 7 | 0.25 | 0.46 | 0.08 |
| Melanoma of skin | 47 (0.39%) | 10 | 4 | 4 | 4 | 5 | 4 | 3 | 13 | 0.25 | 0.47 | 0.12 | |
| Larynx | 47 (0.39%) | 7 | 4 | 9 | 8 | 6 | 4 | 3 | 6 | 0.25 | 0.47 | 0.1 | |
| Vulva | 39 (0.32%) | 3 | 2 | 4 | 4 | 4 | 7 | 6 | 9 | 0.21 | 0.42 | 0.08 | |
| Nasopharynx | 36 (0.30%) | 1 | 17 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 0.19 | 0.28 | 0.04 |
| Salivary glands | 27 (0.22%) | 8 | 2 | 2 | 1 | 2 | 4 | 3 | 5 | 0.14 | 0.27 | 0.07 | |
| Vagina | 20 (0.17%) | 2 | 1 | 1 | 3 | 3 | 3 | 3 | 4 | 0.11 | 0.21 | 0.03 | |
| Kaposi sarcoma | 10 (0.08%) | 6 | 2 | 1 | 1 | 0.05 | 0.07 | 0.01 | |||||
| Mesothelioma | 3 (0.02%) | 1 | 1 | 1 | 0.02 | 0.04 | 0.01 | ||||||
| All cancers excl. non‐melanoma skin cancer | 12 003 (100.00%) | 623 (6.08%) | 3031 (29.58%) | 1127 (11.00%) | 1196 (11.67%) | 1218 (11.89%) | 1184 (11.56%) | 1111 (10.84%) | 961 (9.38%) | 1552 (15.15%) | 63.3 | 108.7 | 17.7 |
Note: The incidence, prevalence proportions (prop.), crude rates, and ASR were reported per 100 000 people.